2,995
Views
3
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness analysis of the SP142 versus 22C3 PD-L1 assays in the treatment of atezolizumab plus nab-paclitaxel for patients with advanced triple negative breast cancer in the Brazilian private healthcare system

, , , &
Pages 1340-1344 | Received 10 Aug 2020, Accepted 03 Sep 2020, Published online: 26 Sep 2020